# A Pharmacokinetics and Safety Study of BIIB132 in Adults With Spinocerebellar Ataxia 3

> **NCT05160558** · PHASE1 · TERMINATED · sponsor: **Biogen** · enrollment: 8 (actual)

## Conditions studied

- Spinocerebellar Ataxia Type 3

## Interventions

- **DRUG:** BIIB132
- **DRUG:** BIIB132-Matching Placebo

## Key facts

- **NCT ID:** NCT05160558
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-02-02
- **Primary completion:** 2023-07-25
- **Final completion:** 2023-07-25
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Sponsor's Decision
- **Last updated:** 2023-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05160558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05160558, "A Pharmacokinetics and Safety Study of BIIB132 in Adults With Spinocerebellar Ataxia 3". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05160558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*